Dawn McNaughton, MD
Family Medicine · Saint Marys, OHNPI 1114980547
Payments from drug & device makers
Across 423 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$745
- Lilly USA, LLC$689
- AbbVie$486
- Pfizer$387
- Boehringer Ingelheim$339
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,839100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,561 |
| Novo Nordisk | 59 | $745 |
| Lilly USA, LLC | 52 | $689 |
| AbbVie(2 entities) | 34 | $486 |
| Pfizer | 28 | $387 |
| Boehringer Ingelheim | 23 | $339 |
| GSK | 20 | $301 |
| Amgen | 20 | $268 |
| Sanofi-aventis U.S. LLC | 18 | $256 |
| Johnson & Johnson | 16 | $248 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $172 |
| Radius Health, Inc. | 9 | $149 |
| Biohaven Pharmaceuticals, Inc. | 10 | $143 |
| Merck | 9 | $142 |
| Abbott | 8 | $138 |
| Biogen | 2 | $88 |
| Bayer | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $74 |
| Novartis | 4 | $60 |
| Amarin Pharma, Inc. | 4 | $58 |
| Boston Scientific | 1 | $57 |
| Exact Sciences | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Nestle Healthcare Nutrition Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Myriad Women's Health, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,856 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $68,541 |
| TrulicityDulaglutide | 38 | $58,459 |
| OzempicSemaglutide | 46 | $54,075 |
| FarxigaDapagliflozin Propanediol | 32 | $44,303 |
| MounjaroTirzepatide | 25 | $40,171 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $27,316 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,227 |
| EliquisApixaban | 15 | $24,227 |
| Praluent PenAlirocumab | 11 | $14,613 |
| XareltoRivaroxaban | 15 | $12,281 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,340 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,067 |
| Atorvastatin Calcium | 291 | $2,325 |
| Novolog FlexpenInsulin Aspart | 14 | $2,046 |
| Metoprolol Succinate | 104 | $1,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $689 | $98,63063 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $339 | $73,88167 claims |
| Novo NordiskOzempic, Levemir | $745 | $55,90958 claims |
| AstraZenecaFarxiga | $1,561 | $44,30332 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $256 | $27,31627 claims |
| GSKTrelegy Ellipta | $301 | $25,22729 claims |
| PfizerEliquis | $387 | $24,22715 claims |
| Johnson & JohnsonXarelto | $248 | $12,28115 claims |
| AbbVieSynthroid | $486 | $1,60088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Saint Marys
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.